全反式维甲酸联合奥沙利铂联合5-氟尿嘧啶/亚叶酸钙(FOLFOX)对比单纯FOLFOX作为晚期肝细胞癌伴肝外转移患者姑息化疗方案的随机对照试验研究方案
本研究为双盲、1:1随机、多中心临床试验,计划纳入368例伴肝外转移的肝细胞癌患者,比较全反式维甲酸(ATRA)联合FOLFOX4与单纯FOLFOX4姑息化疗的疗效。主要终点为总生存率,次要终点包括至疾病进展时间、急慢性不良事件及生活质量。
要点
- ATRA在临床前研究中可提高铂类在肝细胞癌中的疗效,本研究旨在临床验证。
- 计划入组368例晚期肝细胞癌伴肝外转移患者,随机接受ATRA+FOLFOX4或FOLFOX4。
- 主要终点为总生存率,次要终点包括至疾病进展时间、不良事件和生活质量。
核心结论
- 研究旨在验证ATRA联合FOLFOX4对比单纯FOLFOX4能否改善晚期肝细胞癌伴肝外转移患者的疗效。
研究设计与样本
- 双盲、1:1随机、多中心临床试验,计划纳入368例伴肝外转移的肝细胞癌患者。
- 在东方肝胆外科医院、吉林大学第一医院和福建省肿瘤医院接受姑息化疗。
- 受试者随机分配至ATRA+奥沙利铂+5-氟尿嘧啶/亚叶酸钙(FOLFOX4)组或单纯FOLFOX4组。
主要发现
- ATRA 20 mg在FOLFOX4开始前口服,每日三次,连续3天,FOLFOX4结束时停用ATRA。
- 主要终点为总生存率。
- 次要终点为根据mRECIST标准评估的至疾病进展时间、急性和慢性不良事件以及生活质量。
关键数值与推荐
- ATRA剂量为20 mg,口服,每日三次,于FOLFOX4开始前连用3天。
- 主要终点为总生存率;次要终点包括至疾病进展时间(mRECIST标准)、急慢性不良事件和生活质量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed. Prognosis has been quite poor as until recently there was no proven effective chemotherapy. Our group found that all-trans-retinoic acid (ATRA) could improve the efficacy of platinum in HCC in vivo and in vitro, thus we wish to validate the efficiency of ATRA in clinical practice. METHODS: This is a double-blinded, 1:1 randomized, controlled, multicenter clinical trial. Three hundred and sixty-eight patients with HCC and extrahepatic metastases will receive palliative chemotherapy at the Eastern Hepatobiliary Surgery Hospital, First Hospital of Jilin University and Fujian Provincial Cancer Hospital. Subjects will be randomly assigned to one of the two arms, either ATRA + oxaliplatin + 5-fluorouracil/leucovorin (FOLFOX4) or FOLFOX4 alone. ATRA 20 mg will be given orally three times/day for 3 days prior to the initiation of FOLFOX4. ATRA will be discontinued at the end of FOLFOX4. DISCUSSION: Overall survival rate is the primary endpoint. Secondary endpoints are time to progression according to the modified response evaluation criteria in solid tumors (mRECIST) criteria, acute and chronic adverse events, and quality of life. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-IIR-17012916 . Registered on 9 October 2017.
引用
- Shi J, Sun J, Liu C, et al. All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31036040. doi:10.1186/s13063-019-3349-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。